156 related articles for article (PubMed ID: 29748212)
1. TAS-114, a First-in-Class Dual dUTPase/DPD Inhibitor, Demonstrates Potential to Improve Therapeutic Efficacy of Fluoropyrimidine-Based Chemotherapy.
Yano W; Yokogawa T; Wakasa T; Yamamura K; Fujioka A; Yoshisue K; Matsushima E; Miyahara S; Miyakoshi H; Taguchi J; Chong KT; Takao Y; Fukuoka M; Matsuo K
Mol Cancer Ther; 2018 Aug; 17(8):1683-1693. PubMed ID: 29748212
[TBL] [Abstract][Full Text] [Related]
2. First-in-human, phase I dose-escalation study of single and multiple doses of a first-in-class enhancer of fluoropyrimidines, a dUTPase inhibitor (TAS-114) in healthy male volunteers.
Saito K; Nagashima H; Noguchi K; Yoshisue K; Yokogawa T; Matsushima E; Tahara T; Takagi S
Cancer Chemother Pharmacol; 2014 Mar; 73(3):577-83. PubMed ID: 24452393
[TBL] [Abstract][Full Text] [Related]
3. dUTPase inhibition confers susceptibility to a thymidylate synthase inhibitor in DNA-repair-defective human cancer cells.
Yokogawa T; Yano W; Tsukioka S; Osada A; Wakasa T; Ueno H; Hoshino T; Yamamura K; Fujioka A; Fukuoka M; Ohkubo S; Matsuo K
Cancer Sci; 2021 Jan; 112(1):422-432. PubMed ID: 33140501
[TBL] [Abstract][Full Text] [Related]
4. Novel opportunities for thymidylate metabolism as a therapeutic target.
Wilson PM; Fazzone W; LaBonte MJ; Deng J; Neamati N; Ladner RD
Mol Cancer Ther; 2008 Sep; 7(9):3029-37. PubMed ID: 18790783
[TBL] [Abstract][Full Text] [Related]
5. [5-fluorouracil and dihydropyrimidine dehydrogenase].
Kubota T
Gan To Kagaku Ryoho; 2001 Apr; 28(4):433-9. PubMed ID: 11329775
[TBL] [Abstract][Full Text] [Related]
6. Correlations between antitumor activities of fluoropyrimidines and DPD activity in lung tumor xenografts.
Takechi T; Okabe H; Ikeda K; Fujioka A; Nakagawa F; Ohshimo H; Kitazato K; Fukushima M
Oncol Rep; 2005 Jul; 14(1):33-9. PubMed ID: 15944764
[TBL] [Abstract][Full Text] [Related]
7. [Dihydropyrimidine déhydrogenase (DPD) deficiency screening and securing of fluoropyrimidine-based chemotherapies: Update and recommendations of the French GPCO-Unicancer and RNPGx networks].
Loriot MA; Ciccolini J; Thomas F; Barin-Le-Guellec C; Royer B; Milano G; Picard N; Becquemont L; Verstuyft C; Narjoz C; Schmitt A; Bobin-Dubigeon C; Harle A; Paci A; Poinsignon V; Quaranta S; Evrard A; Hennart B; Broly F; Fonrose X; Lafay-Chebassier C; Wozny AS; Masskouri F; Boyer JC; Etienne-Grimaldi MC
Bull Cancer; 2018 Apr; 105(4):397-407. PubMed ID: 29486921
[TBL] [Abstract][Full Text] [Related]
8. Enhancement of the antitumour activity of 5-fluorouracil (5-FU) by inhibiting dihydropyrimidine dehydrogenase activity (DPD) using 5-chloro-2,4-dihydroxypyridine (CDHP) in human tumour cells.
Takechi T; Fujioka A; Matsushima E; Fukushima M
Eur J Cancer; 2002 Jun; 38(9):1271-7. PubMed ID: 12044515
[TBL] [Abstract][Full Text] [Related]
9. The Evaluation of Dihydropyrimidine Dehydrogenase Enzyme Level in the Serum of Colorectal Cancer Iraqi Males on Fluoropyrimidine-Based Chemotherapy (Capecitabine).
Challoob MA; Mohammed NS
Cureus; 2023 Sep; 15(9):e44534. PubMed ID: 37790008
[TBL] [Abstract][Full Text] [Related]
10. A novel combination antimetabolite, TAS-102, exhibits antitumor activity in FU-resistant human cancer cells through a mechanism involving FTD incorporation in DNA.
Emura T; Suzuki N; Yamaguchi M; Ohshimo H; Fukushima M
Int J Oncol; 2004 Sep; 25(3):571-8. PubMed ID: 15289858
[TBL] [Abstract][Full Text] [Related]
11. Augmentation of the antitumor activity of capecitabine by a tumor selective dihydropyrimidine dehydrogenase inhibitor, RO0094889.
Endo M; Miwa M; Eda H; Ura M; Tanimura H; Ishikawa T; Miyazaki-Nose T; Hattori K; Shimma N; Yamada-Okabe H; Ishitsuka H
Int J Cancer; 2003 Sep; 106(5):799-805. PubMed ID: 12866042
[TBL] [Abstract][Full Text] [Related]
12. dUTPase inhibition augments replication defects of 5-Fluorouracil.
Hagenkort A; Paulin CBJ; Desroses M; Sarno A; Wiita E; Mortusewicz O; Koolmeister T; Loseva O; Jemth AS; Almlöf I; Homan E; Lundbäck T; Gustavsson AL; Scobie M; Helleday T
Oncotarget; 2017 Apr; 8(14):23713-23726. PubMed ID: 28423595
[TBL] [Abstract][Full Text] [Related]
13. dUTP nucleotidohydrolase isoform expression in normal and neoplastic tissues: association with survival and response to 5-fluorouracil in colorectal cancer.
Ladner RD; Lynch FJ; Groshen S; Xiong YP; Sherrod A; Caradonna SJ; Stoehlmacher J; Lenz HJ
Cancer Res; 2000 Jul; 60(13):3493-503. PubMed ID: 10910061
[TBL] [Abstract][Full Text] [Related]
14. DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update.
Henricks LM; Opdam FL; Beijnen JH; Cats A; Schellens JHM
Ann Oncol; 2017 Dec; 28(12):2915-2922. PubMed ID: 29045513
[TBL] [Abstract][Full Text] [Related]
15. Development of new promising antimetabolite, DFP-11207 with self-controlled toxicity in rodents.
Fukushima M; Iizuka K; Jin C; Zhang C; Hong M; Eshima K
Drug Des Devel Ther; 2017; 11():1693-1705. PubMed ID: 28652707
[TBL] [Abstract][Full Text] [Related]
16. Dihydropyrimidine dehydrogenase inhibition as a strategy for the oral administration of 5-fluorouracil: utility in the treatment of advanced colorectal cancer.
Schmoll HJ
Anticancer Drugs; 2003 Oct; 14(9):695-702. PubMed ID: 14551502
[TBL] [Abstract][Full Text] [Related]
17. Prediction of sensitivity to fluoropyrimidines by metabolic and target enzyme activities in gastric cancer.
Terashima M; Fujiwara H; Takagane A; Abe K; Irinoda T; Nakaya T; Yonezawa H; Oyama K; Saito K; Kanzaki N; Ohtani S; Nemoto T; Hoshino Y; Kogure M; Gotoh M
Gastric Cancer; 2003; 6 Suppl 1():71-81. PubMed ID: 12775024
[TBL] [Abstract][Full Text] [Related]
18. Role of dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine against non-small cell lung cancer--in correlation with the tumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase.
Inoue K; Takao M; Watanabe F; Tarukawa T; Shimamoto A; Kaneda M; Sakai T; Fukushima M; Shimpo H; Yada I
Lung Cancer; 2005 Jul; 49(1):47-54. PubMed ID: 15949589
[TBL] [Abstract][Full Text] [Related]
19. 5-fluorouracil and dihydropyrimidine dehydrogenase.
Kubota T
Int J Clin Oncol; 2003 Jun; 8(3):127-31. PubMed ID: 12851835
[TBL] [Abstract][Full Text] [Related]
20. Dihydropyrimidine dehydrogenase inhibitory fluoropyrimidines: a novel class of oral antineoplastic agents.
Hoff PM; Pazdur R
Semin Oncol; 1999 Dec; 26(6 Suppl 18):52-6. PubMed ID: 10892578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]